Ono Pharmaceutical (OTCMKTS:OPHLF) Stock Price Up 14.2% - Should You Buy?

Key Points

• Ono Pharmaceutical's stock surged 14.2% during mid-day trading, reaching a price of $11.82, while trading volume significantly declined to 254 shares, far below the average of 8,651 shares.
• Despite the positive stock movement, the company missed earnings expectations for the latest quarter, reporting earnings per share of $0.26 compared to the expected $0.34.
• Ono Pharmaceutical has a market capitalization of $5.55 billion and maintains a strong financial position with a current ratio of 2.99 and a relatively low debt-to-equity ratio of 0.13.

Ono Pharmaceutical Co. (OTCMKTS:OPHLF - Get Free Report) shares rose 14.2% during trading on Thursday . The stock traded as high as $11.82 and last traded at $11.82. Approximately 254 shares were traded during mid-day trading, a decline of 97% from the average daily volume of 8,651 shares. The stock had previously closed at $10.35.

Ono Pharmaceutical Trading Up 14.2%

The stock has a market capitalization of $5.55 billion, a P/E ratio of 19.06 and a beta of 0.17. The company has a current ratio of 2.99, a quick ratio of 2.44 and a debt-to-equity ratio of 0.13. The company has a 50-day moving average price of $11.22 and a 200 day moving average price of $10.96.

Ono Pharmaceutical (OTCMKTS:OPHLF - Get Free Report) last announced its earnings results on Monday, August 4th. The company reported $0.26 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.34 by ($0.08). Ono Pharmaceutical had a net margin of 8.75% and a return on equity of 5.47%. The business had revenue of $886.27 million for the quarter, compared to analyst estimates of $827.29 million.

Ono Pharmaceutical Company Profile

Ono Pharmaceutical Co, Ltd., together with its subsidiaries, produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It offers Opdivo Intravenous Infusion and Kyprolis Intravenous Injection for malignant tumors; Emend capsules/Proemend intravenous injections for chemotherapy-induced nausea and vomiting; Demser capsules for the symptoms in patients with pheochromocytoma; and Mektovi, Velexbru, and Braftovi capsules for malignant tumors, as well as ADLUMIZ tablets for cancer cachexia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.